XTX Topco’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

XTX Topco’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-520	Closed	-$4.76K	–	2287
2023 Q3	$4.76K	Sell	520 -1,356	-72%	-$27.3K	﹤0.01%	1467
2023 Q2	$39.6K	Sell	1,876 -4,899	-72%	-$151K	0.01%	1266
2023 Q1	$182K	Sell	6,775 -2,836	-30%	-$132K	0.04%	983
2022 Q4	$340K	Buy	+9,611	New	+$1.15M	0.07%	507
2022 Q3	–	Sell	-1,290	Closed	-$244K	–	1454
2022 Q2	$244K	Buy	+1,290	New	+$260K	0.1%	370

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

XTX Topco's EIGR Position: Q4 2023 in Review

XTX Topco sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2023, closing a stake of 520 shares — an estimated $4.76K sold.

XTX Topco first reported a position in EIGR in Q2 2022 and held it in 5 quarters. The position peaked at $340K in Q4 2022. 43 funds tracked by Wall St. Rank hold EIGR as of Q4 2023.

XTX Topco reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
XTX Topco sold 520 Eiger BioPharmaceuticals, Inc. shares in Q4 2023, an estimated $4.76K.
XTX Topco first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2022 and held it in 5 quarters.
XTX Topco's Eiger BioPharmaceuticals, Inc. position peaked at $340K in Q4 2022.
43 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2023.

Based on XTX Topco's 13F filing for Q4 2023, filed 13 Feb 2024.